Portal Hypertension VII

PART I) INTRODUCTORY LECTURES.- Chapter 1) Introduction: Baveno I to Baveno VII.. and Beyond.- Chapter 2) New Concepts in Risk Stratification.- Chapter 3) Clinical Stages and Ordinal Outcomes in Portal Hypertension.- Chapter 4) Lifestyle and Genetic Modifiers of Liver Disease Progression.- PART II) HVPG AS A GOLD STANDARD.- Chapter 5) HVPG as a Gold Standard: Accuracy Is Essential.- Chapter 6) Consensus Statements, Panel 1: HVPG as a Gold Standard.- PART III NONINVASIVE TOOLS FOR cACLD AND PORTAL HYPERTENSION.- Chapter 7) Results of the Baveno VII Questionnaire on the Use of Non-Invasive Tools for cACLD and Portal Hypertension.- Chapter 8) Compensated Advanced Chronic Liver Disease (cACLD).- Chapter 9) Non-Invasive Detection of Clinically Significant Portal Hypertension with Liver Elastography.- Chapter 10) Varices and Screening Endoscopy.- Chapter 11) Liver Elastography for Prognostication and Monitoring Patients with Compensated Advanced Chronic Liver Disease.- Chapter 12) SpleenStiffness.- Chapter 13) Emerging Non-Invasive Markers: Imaging, Blood, and Liver Clearance Tests.- Chapter 14) Consensus Statements, Panel 2: Non-Invasive Surrogates for cACLD, CSPH, Varices.- PART IV) NEW SCENARIOS 1: INTRODUCTORY LECTURES: PROGRESSION AND REGRESSION OF CIRRHOSIS.- Chapter 15) Progression and Regression of Cirrhosis: The Histologic Perspective.- Chapter 16) Liver Fibrosis and Its Regression in the Context of Portal Hypertension.- Chapter 17) Angiogenesis and Progression of ACLD.- Chapter 18) Drugs to Modify Liver Fibrosis Progression and Regression.- PART V) NEW SCENARIOS 2 - MANAGEMENT OF ACLD AFTER REMOVAL OF THE PRIMARY ETIOLOGICAL FACTOR.- Chapter 19) Therapies for Alcohol-Related Liver Disease and for Non-Alcoholic Fatty Liver Disease.- Chapter 20) Management of ACLD after HBV-Suppression and HCV-Cure- Chapter 21) Consensus Statements, Panel 3: Management of ACLD after Removal/Suppression of the Etiological Factor.- PART VI) NEW SCENARIOS 3 - IMPACT OF NON-ETIOLOGICAL NOVEL THERAPIES IN THE COURSE OF CIRRHOSIS.- Chapter 22) Results of the Baveno VII Questionnaire on the "Impact of Non-Etiological Therapies in the Course of Cirrhosis.- Chapter 23) Statins in Compensated and Decompensated Cirrhosis: Approaching the Bedside.- Chapter 24) Anticoagulation for Portal Vein Thrombosis in Cirrhosis: an Evidence-Based Approach to When and How.- Chapter 25) Novel Approaches & Disease Modifiers to Alter the Course of Cirrhotic Portal Hypertension.- Chapter 26) Targeting the Gut Microbiome in Cirrhosis.- Chapter 27) Impact of Non-Etiological Novel Therapies in the Course of Cirrhosis - Consensus Statements of Panel 4.- PART VII) CLINICAL SETTINGS 1 - PREVENTING (FIRST) DECOMPENSATION.- Chapter 28) Prevention of First Decompensation: Questionnaire.- Chapter 29) Definition of First Decompensation in Cirrhosis.- Chapter 30) Evaluation of the Impact of the Sole Presence of Infection (Without Accompanying Decompensation) in the Natural History of Compensated Cirrhosis- Chapter 31) Evaluation of the Role of Jaundice in the Definition of Decompensation in the Compensated Patients.- Chapter 32) Evaluation of the Role of Minimal Perihepatic Ascites, Minimal Hepatic Encephalopathy, and Bleeding due to Portal Hypertensive Gastroenteropathy in the Definition of Decompensation.- Chapter 33) Evaluation of the Role of Sarcopenia in the Definition of Decompensation of the Compensated Patient.- Chapter 34) ß-blockers to Prevent Decompensation of Cirrhosis in Compensated Patients with Clinically Significant Portal Hypertension- Chapter 35) Evaluation of the Effect of CSPH, Reduction of HVPG, and Other Factors Predicting the First Decompensation in Cirrhosis.- Chapter 36) Preventing (First) Decompensation - Consensus Statements of Panel 5.- PART VIII) CLINICAL SETTINGS 2 - ACUTE VARICEAL BLEEDING.- Chapter 37) General Management of Acute Variceal Bleeding.- Chapter 38) Risk Stratification and Prognostic Factors in Variceal Bleeding.- Chapter 39) Endoscopic Management: Classic and New Therapies.- Chapter 40) Preemptive TIPS (p-TIPS).- Chapter 41) Management of Refractory Variceal Bleeding.- Chapter 42) Hepatic Encephalopathy and Acute Variceal Bleeding.- Chapter 43) Management of Coagulation in Acute Variceal Bleeding.- Chapter 44) Gastric Varices and Ectopic Varice.- Chapter 45) Special Settings: Acute Variceal Bleeding and Portal Vein Thrombosis in Cirrhosis.- Chapter 46) Clinical Settings 2 - Acute Variceal Bleeding - Consensus Statements of Panel 6.- PART IX) CLINICAL SETTINGS 3 - PREVENTING FURTHER DECOMPENSATION.- Chapter 47) Concept of Further Decompensation and Recompensation.- Chapter 48) Prevention of Variceal Bleeding and Rebleeding.- Chapter 49) Prevention of Further Decompensation in Patients with Ascites.- Chapter 50) The Impact of Sarcopenia, Frailty, and Malnutrition on Further Decompensation.- Chapter 51) Preventing Further Decompensation. Consensus Statements of Panel 7.- PART X) VASCULAR LIVER DISORDERS 1 - SPLANCHNIC VEIN THROMBOSIS.- Chapter 52) Portal Vein Thrombosis. Anticoagulation Versus Interventional Radiology.- Chapter 53) Staging of Portal Vein Thrombosis. Recurrent Thrombosis and Prognostic Factors for Recurrence in Non-Cirrhotic Non-Tumoral Portal Vein Thrombosis (PVT).- Chapter 54) Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis.- Chapter 55) Splanchnic Vein Thrombosis - Consensus Statements of Panel 8.- PART XI) VASCULAR LIVER DISORDERS 2 - OTHER ISSUES IN VASCULAR LIVER DISORDERS.- Chapter 56) Porto-Sinusoidal Vascular Disorder.- Chapter 57) Anticoagulation in Splanchnic Vein Thrombosis with and without Underlying Liver Disease.- Chapter 58) Medical Approach to Fontan Patients.- Chapter 59) Other Issues in Vascular Liver Disorders - Consensus Statements of Panel 9.